MX2021004471A - Derivados de pirrolo-pididazina como moduladores alostéricos positivos del receptor muscarínico m1. - Google Patents

Derivados de pirrolo-pididazina como moduladores alostéricos positivos del receptor muscarínico m1.

Info

Publication number
MX2021004471A
MX2021004471A MX2021004471A MX2021004471A MX2021004471A MX 2021004471 A MX2021004471 A MX 2021004471A MX 2021004471 A MX2021004471 A MX 2021004471A MX 2021004471 A MX2021004471 A MX 2021004471A MX 2021004471 A MX2021004471 A MX 2021004471A
Authority
MX
Mexico
Prior art keywords
muscarinic
positive allosteric
receptor positive
allosteric modulators
pyrrolo
Prior art date
Application number
MX2021004471A
Other languages
English (en)
Inventor
Anil Karbhari Shinde
Abdul Rasheed Mohammed
Venkateswarlu Jasti
Ramakrishna Nirogi
Srinivasa Rao Ravella
Ramkumar Subramanian
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MX2021004471A publication Critical patent/MX2021004471A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención está relacionada a compuestos de fórmula (I), o sus formas isotópicas, estereoisómeros, tautómeros o sales farmacéuticamente aceptables como moduladores alostéricos positivos del receptor M1 muscarínico (M1 PAMs); la presente invención describe la preparación, la composición farmacéutica y el uso de tales compuestos.
MX2021004471A 2018-10-17 2019-10-16 Derivados de pirrolo-pididazina como moduladores alostéricos positivos del receptor muscarínico m1. MX2021004471A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841039345 2018-10-17
PCT/IB2019/058815 WO2020079606A1 (en) 2018-10-17 2019-10-16 Pyrrolo-pyridazine derivatives as muscarinic m1 receptor positive allosteric modulators

Publications (1)

Publication Number Publication Date
MX2021004471A true MX2021004471A (es) 2021-08-24

Family

ID=68470570

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004471A MX2021004471A (es) 2018-10-17 2019-10-16 Derivados de pirrolo-pididazina como moduladores alostéricos positivos del receptor muscarínico m1.

Country Status (13)

Country Link
EP (1) EP3867254B1 (es)
JP (1) JP7140915B2 (es)
KR (1) KR102607510B1 (es)
CN (1) CN113166160B (es)
AU (1) AU2019362468B2 (es)
BR (1) BR112021007168A2 (es)
CA (1) CA3116506C (es)
EA (1) EA202191046A1 (es)
IL (1) IL282336B (es)
MA (1) MA53917A (es)
MX (1) MX2021004471A (es)
WO (1) WO2020079606A1 (es)
ZA (1) ZA202102487B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3700895B1 (en) * 2017-10-27 2021-09-22 Suven Life Sciences Limited Polycyclic amides as muscarinic m1 receptor positive allosteric modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0317358A (pt) * 2003-01-09 2005-12-13 Astellas Pharma Inc Composto de pirrolopiridazina, processo para sua preparação, composição farmacêutica contendo o mesmo, método de prevenção ou tratamento de doenças contendo o mesmo e seu uso
BR112012014180A2 (pt) 2009-12-17 2015-09-15 Merck Sharp & Dohme composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio.
US8883850B2 (en) 2010-05-28 2014-11-11 Merck Sharp & Dohme Corp. Naphthalene carboxamide M1 receptor positive allosteric modulators
WO2011159554A1 (en) 2010-06-15 2011-12-22 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide m1 receptor positive allosteric modulators
RU2016132858A (ru) 2014-01-22 2018-03-02 Ф. Хоффманн-Ля Рош Аг Производные фторнафтила
KR101730272B1 (ko) * 2015-12-28 2017-04-26 씨제이헬스케어 주식회사 피롤로피리다진 유도체를 포함하는 단백질 키나제 억제제
MD3507289T2 (ro) 2016-09-02 2020-11-30 Suven Life Sciences Ltd Modulatori alosterici pozitivi ai receptorilor muscarinici M1
US10899759B2 (en) * 2016-09-30 2021-01-26 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
WO2018194181A1 (en) 2017-04-18 2018-10-25 Takeda Pharmaceutical Company Limited Heterocyclic compounds useful as modulators of acetylcholine receptors
EP3697790B1 (en) * 2017-10-18 2023-01-18 Suven Life Sciences Limited Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators

Also Published As

Publication number Publication date
CA3116506C (en) 2023-08-01
BR112021007168A2 (pt) 2021-08-10
WO2020079606A9 (en) 2020-08-13
CA3116506A1 (en) 2020-04-23
AU2019362468A1 (en) 2021-05-20
AU2019362468B2 (en) 2022-04-21
EP3867254B1 (en) 2023-05-31
IL282336B (en) 2022-01-01
IL282336A (en) 2021-05-31
WO2020079606A1 (en) 2020-04-23
US20210340148A1 (en) 2021-11-04
KR102607510B1 (ko) 2023-11-30
JP7140915B2 (ja) 2022-09-21
KR20210079320A (ko) 2021-06-29
ZA202102487B (en) 2022-10-26
JP2022505401A (ja) 2022-01-14
MA53917A (fr) 2022-01-26
NZ775905A (en) 2024-01-26
EP3867254A1 (en) 2021-08-25
CN113166160A (zh) 2021-07-23
CN113166160B (zh) 2023-12-19
EA202191046A1 (ru) 2021-07-12

Similar Documents

Publication Publication Date Title
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
MX2021004000A (es) Derivados de piperidina.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
PH12019502562A1 (en) N-substituted indole derivatives
NZ763341A (en) Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
MX2017011978A (es) Analogos deuterados de etifoxina, sus derivados y usos de estos.
TN2020000009A1 (en) Estrogen receptor modulators
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
MX2020013291A (es) Derivados de piridinilo alcoxisustituido como antagonistas del receptor lpa1 y su uso en el tratamiento de la fibrosis.
NZ764004A (en) Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
MX2021004471A (es) Derivados de pirrolo-pididazina como moduladores alostéricos positivos del receptor muscarínico m1.
TN2018000175A1 (en) Indane derivatives as mglur7 modulators
PH12017501736A1 (en) Indole derivatives
PH12017500323B1 (en) P38 map kinase inhibiting indanyl urea compounds
MX2021015727A (es) Derivados de piridin-3-ilo.
EA202090397A1 (ru) Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht-рецептора
NZ764561A (en) Substituted azacycles as muscarinic m1 receptor positive allosteric modulators
EA201990534A1 (ru) Позитивные аллостерические модуляторы мускариновых m1–рецепторов
ZA202206436B (en) Macrocyclic pantetheine derivatives and uses thereof